ALTIMMUNE
Altimmune is an emerging biotechnology company located in Montgomery County, MD. Altimmune develops vaccines and other biological products to address unmet market and public health needs. The company uses a proprietary technology for non-invasive intranasal delivery, and has shown proof of principle in animals and in initial human clinical studies. Vaxin Inc., formerly known as Vaxin Pharmaceuticals and ImmuneFocus Corporation, was founded in 1997 by Emerging Technology Partners. Early experiments revealed that DNA incorporated into an adenovirus can elicit an immune response when placed on the surface of the skin, and subsequently research was expanded to include applications on the skin in the nose as well as experimentation with other vectors.
ALTIMMUNE
Industry:
Biotechnology Clinical Trials Health Care Test And Measurement
Founded:
1997-01-01
Address:
Gaithersburg, Maryland, United States
Country:
United States
Website Url:
http://www.altimmune.com
Total Employee:
11+
Status:
Active
Contact:
8555571369
Email Addresses:
[email protected]
Total Funding:
51.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-07-09 | Spitfire Pharma | Spitfire Pharma acquired by Altimmune | 93 M USD |
| 2017-01-19 | PharmAthene | PharmAthene acquired by Altimmune | N/A |
| 2015-02-17 | Immune Targeting Systems | Immune Targeting Systems acquired by Altimmune | N/A |
Investors List
Biomedical Advanced Research and Development Authority (BARDA)
Biomedical Advanced Research and Development Authority (BARDA) investment in Grant - Altimmune
HealthCap
HealthCap investment in Post-IPO Equity - Altimmune
Novartis Venture Fund
Novartis Venture Fund investment in Post-IPO Equity - Altimmune
Redmont Capital
Redmont Capital investment in Post-IPO Equity - Altimmune
Truffle Capital
Truffle Capital investment in Post-IPO Equity - Altimmune
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-13 | Altimmune Appoints Richard Eisenstadt as Chief Financial Officer |
Official Site Inspections
http://www.altimmune.com Semrush global rank: 4.94 M Semrush visits lastest month: 1.73 K
- Host name: cloudproxy10064.sucuri.net
- IP address: 192.124.249.64
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Altimmune"
Altimmune - Crunchbase Company Profile & Funding
Altimmune focused on the development of products to stimulate robust and durable immune responses for the prevention.See details»
Altimmune, Inc. - LinkedIn
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s …See details»
Altimmune, Inc. (ALT) Company Profile & Facts - Yahoo Finance
See the company profile for Altimmune, Inc. (ALT) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Altimmune Company Profile - Office Locations, Competitors ... - Craft
Altimmune has 5 employees at their 1 location and $426 k in annual revenue in FY 2023. See insights on Altimmune including office locations, competitors, revenue, financials, executives, …See details»
Altimmune - 2025 Company Profile & Team - Tracxn
3 days ago Explore Altimmune's in-depth company profile, including funding details, key investors, leadership, competitors, and acquisitions.See details»
Altimmune - The Org
Altimmune is a clinical stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. We strategically employ our two …See details»
Altimmune a clinical stage biopharmaceutical company
Altimmune a clinical stage biopharmaceutical company developing peptide-based therapeutics. Our focus is developing next generation peptide therapeutics for obesity and liver diseaseSee details»
What Is the Brief History of Altimmune Company?
Jul 11, 2025 Altimmune's journey highlights a strategic evolution from vaccine development to a broader focus on immunotherapies. 1997: Vaxin Inc. is founded, laying the groundwork for …See details»
Altimmune, Inc. (ALT): history, ownership, mission, how it works ...
Explore ALTimmune's history and ownership. Learn its mission, how it works, and revenue strategies. Get insights into its sustainable growth.See details»
Thank you, Altimmune, Inc.! - Obesity Action Coalition
Mar 14, 2024 To learn more, visit Altimmune.com. About the OAC Chairman’s Council The OAC is honored that Altimmune, Inc. has chosen to support our organization at the Patron level through the Chairman’s Council as we strive …See details»
Altimmune Announces Second Quarter 2025 Financial Results
2 days ago About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases.See details»
Board of Directors – Altimmune
The Investor Relations website contains information about Altimmune's business for stockholders, potential investors, and financial analysts.See details»
Individual investors account for 51% of Altimmune, Inc.'s …
1 day ago The considerable ownership by individual investors in Altimmune indicates that they collectively have a greater say in management and business strategy The top 25 shareholders …See details»
Altimmune – Investors Overview
Jun 26, 2025 The Investor Relations website contains information about Altimmune's business for stockholders, potential investors, and financial analysts.See details»
Altimmune Announces Second Quarter 2025 Financial Results and …
Jun 30, 2025 The Investor Relations website contains information about Altimmune's business for stockholders, potential investors, and financial analysts.See details»
Press Releases – Altimmune
May 14, 2025 The Investor Relations website contains information about Altimmune's business for stockholders, potential investors, and financial analysts.See details»
Executive Team | Altimmune Website
910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450See details»
Board of Directors | Altimmune Website
910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450See details»
Altimmune Announces Initiation of RESTORE Phase 2 Trial …
GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics …See details»
Altimmune Board of Directors Appoints Jerry Durso as Chairman
3 days ago The Investor Relations website contains information about Altimmune's business for stockholders, potential investors, and financial analysts.See details»